Interleukins are cytokines or small signaling proteins that are secreted by various immune cells and help regulate inflammatory and immunologic responses. Rise in various autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease etc. have increased the demand for interleukin inhibitors that can inhibit specific interleukins and provide relief from symptoms.
The global interleukin inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.
Key Takeaways
AbbVie Inc., Johnson Johnson, Amgen Inc., Novartis AG, Sanofi S.A., GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Merck Co., Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Astellas Pharma Inc., Bayer AG, and Sandoz International GmbH.
Rise in autoimmune diseases globally has emerged as a major driver of growth for Interleukin Inh Market Trends. According to some estimates, autoimmune diseases affect nearly 24 million Americans annually. Increasing cases has fueled the demand for more effective interleukin inhibitors drugs.
Technological advancements have allowed development of novel biologics with improved selectivity for specific interleukins leading to better efficacy and safety profiles. Many pipeline drugs target novel interleukins and offer enhanced treatment outcomes in autoimmune conditions.
Get More Insights on- Interleukin Inhibitors Market
